Results 211 to 220 of about 414,852 (267)
Some of the next articles are maybe not open access.
Wiener Medizinische Wochenschrift, 2011
Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus. In type 2 diabetes, insulin is indicated if glycaemic goals are not reached by oral anti diabetics, as well as for metabolic detoriation, co-morbidities, surgery, pregnancy or contradictions against oral anti diabetics.
Monika, Lechleitner +1 more
openaire +2 more sources
Insulin therapy is a vital hormone replacement therapy in type 1 diabetes mellitus. In type 2 diabetes, insulin is indicated if glycaemic goals are not reached by oral anti diabetics, as well as for metabolic detoriation, co-morbidities, surgery, pregnancy or contradictions against oral anti diabetics.
Monika, Lechleitner +1 more
openaire +2 more sources
Veterinary Clinics of North America: Small Animal Practice, 1995
Insulin therapy is the most important treatment aspect of diabetes mellitus. Since the discovery of insulin in 1921, a variety of insulin formulations have been developed. The purpose of this article is to describe the current sources, formulations, and types of insulins available for therapy of diabetes mellitus in small animals and to provide the ...
D S, Greco +2 more
openaire +2 more sources
Insulin therapy is the most important treatment aspect of diabetes mellitus. Since the discovery of insulin in 1921, a variety of insulin formulations have been developed. The purpose of this article is to describe the current sources, formulations, and types of insulins available for therapy of diabetes mellitus in small animals and to provide the ...
D S, Greco +2 more
openaire +2 more sources
American Journal of Therapeutics, 2020
Background: Advances in pump technology have increased the popularity of this treatment modality among patients with type 1 diabetes and recently also among patients with type 2 diabetes. Areas of Uncertainty: Four decades after the incorporation of the insulin pump in clinical use,
Revital, Nimri +2 more
openaire +2 more sources
Background: Advances in pump technology have increased the popularity of this treatment modality among patients with type 1 diabetes and recently also among patients with type 2 diabetes. Areas of Uncertainty: Four decades after the incorporation of the insulin pump in clinical use,
Revital, Nimri +2 more
openaire +2 more sources
Intensive Insulin Therapy and Insulin Pumps
Postgraduate Medicine, 2002The introduction of intensive insulin therapy can be a difficult transition for patients who have diabetes mellitus. A carefully designed treatment program will help keep patients motivated and informed. Selecting the most appropriate insulin regimen and delivery system for patients' individual needs can help patients make a smoother transition to ...
openaire +2 more sources
Insulin Detemir and Basal Insulin Therapy
Endocrinology and Metabolism Clinics of North America, 2007With the introduction of insulin detemir (Levemir [Novo Nordisk A/S, Bagsvaerd, Denmark]), a long-acting basal insulin analog, it is an opportune moment to reevaluate the use of basal insulin therapy and consider current treatment strategies, including the use of insulin detemir.
openaire +3 more sources
Current Diabetes Reports, 2004
The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with a major stumbling block being the perceived complexity of insulin. However, this complexity can be easily overcome by separation of insulin administration into its two components ...
John N, Clore, Linda, Thurby-Hay
openaire +2 more sources
The initiation of insulin therapy is a significant event for patients with diabetes and the physicians who care for them. Reluctance to begin insulin is multifactorial, with a major stumbling block being the perceived complexity of insulin. However, this complexity can be easily overcome by separation of insulin administration into its two components ...
John N, Clore, Linda, Thurby-Hay
openaire +2 more sources
Current Opinion in Endocrinology, Diabetes & Obesity, 2008
In a 2001 report from a surgical intensive care unit in Leuven, Belgium, intravenous insulin infusion targeting blood glucose 80-110 mg/dl reduced patient mortality and morbidities. Subsequent research has failed to define glycemic targets necessary or sufficient for attainment of desired health outcomes in other inpatient settings, but a large body of
openaire +2 more sources
In a 2001 report from a surgical intensive care unit in Leuven, Belgium, intravenous insulin infusion targeting blood glucose 80-110 mg/dl reduced patient mortality and morbidities. Subsequent research has failed to define glycemic targets necessary or sufficient for attainment of desired health outcomes in other inpatient settings, but a large body of
openaire +2 more sources
Drug and Therapeutics Bulletin, 2012
Insulin pump therapy makes use of an external device to deliver insulin continuously from a refillable storage reservoir by means of a cannula placed under the skin. A pump is intended to simulate pancreatic function in that it can be programmed to deliver an adjustable basal rate of insulin throughout the day, with higher infusion ...
openaire +2 more sources
Insulin pump therapy makes use of an external device to deliver insulin continuously from a refillable storage reservoir by means of a cannula placed under the skin. A pump is intended to simulate pancreatic function in that it can be programmed to deliver an adjustable basal rate of insulin throughout the day, with higher infusion ...
openaire +2 more sources
Diabetes/Metabolism Research and Reviews, 2002
The prevalence of type 1 diabetes is rising in all European countries, particularly in Scandinavia and the UK. Insulin therapy in Europe is strongly influenced by the results of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), both of which showed the importance of tight metabolic control in
openaire +2 more sources
The prevalence of type 1 diabetes is rising in all European countries, particularly in Scandinavia and the UK. Insulin therapy in Europe is strongly influenced by the results of the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), both of which showed the importance of tight metabolic control in
openaire +2 more sources